Abstract
A large proportion of COVID-19 research has been focused on identifying markers of high-risk individuals. However, this research often fails to consider basic epidemiologic concepts to prevent bias in the design, selection, and analysis of observational data. One suspected marker of risk that has been repeatedly assessed is ABO blood type. Given the ease of measuring this biomarker, it is an appealing target for identifying high-risk individuals. However, this same ease of measurement makes associational research on ABO blood type and COVID prone to a range of common epidemiologic errors. We conducted a systematic review of studies assessing correlations between ABO blood type and COVID incidence, hospitalization, and mortality to determine the quality of evidence these studies provide and whether the overall evidence suggests ABO blood type could provide a useful indicator of COVID risk. We conclude that most existing studies are low quality and suffer from major methodological flaws. The few higher-quality studies which do exist find no association between ABO blood type and COVID outcomes. We conclude that there is no evidence to support the use of ABO blood type as a marker for COVID risk or severity.
Key Points
There is no sufficient evidence to conclude a biological relationship between ABO blood types and COVID-19 infection or severity.
Biases of existing research could be avoided by careful study design.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Epidemiologic COVID-19 Response Corps at Boston University School of Public Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not human subjects research.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data extraction tables are available upon request.
